Facio BioTherapies Pty Revenue
Biotechnology Research • 
Sydney, New South Wales, Australia • 1-10 Employees
Facio BioTherapies Pty revenue & valuation
| Annual revenue | $598,885 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | No funding |
Key Contacts at Facio BioTherapies Pty
Andrew Weekes
Non Executive Director
Natalie Cooney
Director
Company overview
| Headquarters | Sydney, New South Wales, Australia |
| Phone number | +6120092019 |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Biomarkers, Chemistry, Discovery, Biopharmaceuticals, Diagnostics, Regulatory Affairs, Commercialisation, Genomics, Market Access, Regeneration, Neurodegeneration, Muscle Biology, Neuromuscular Disease, Scientific Affairs, Nucleic Acid Therapies |
| Founded | 2021 |
| Employees | 1-10 |
Facio BioTherapies Pty Email Formats
Facio BioTherapies Pty uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@faciobt.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@faciobt.com | 100% |
About Facio BioTherapies Pty
Facio BioTherapies Pty Limited (“FACIO”) was founded in 2021 in collaboration with the FSHD Global Research Foundation to focus solely on discovering and developing innovative diagnostic solutions and targeted therapies for Facioscapulohumeral Muscular Dystrophy (FSHD). FACIO is a pre-clinical stage biotechnology company headquartered in Australia, with research collaborations in Melbourne, Sydney, Washington DC, and Seattle Washington. FSHD Global Research Foundation is a patient-led, philanthropic foundation. Since its inception in 2008, the FOUNDATION has disbursed grants of >$20 million to enable discovery, diagnostic, biomarker and clinical research. FSH muscular dystrophy (FSHD) is a highly complex muscle wasting disease causing progressive weakness that affects over one million people globally. The condition is caused by a toxic gain of function genetic alteration in a transcription factor (DUX4) that is normally silenced after embryonic development. Currently there are no approved treatments for FSHD and the condition suffers from lack of investment in basic and translational research. FACIO's VISION is to transform the standard of care and to ultimately cure FSHD. Our MISSION is to develop best-in-disease, targeted therapies that: 1) modify the toxic genes that cause FSHD, 2) are muscle tissue targeting 3) have disease modifying potential, 4) are safe and well tolerated and 5) are durable in mechanism of action. FACIO is connecting with FSHD Patient Advocacy Groups in Australia and Globally to ensure we embed the patient voice and experience in co-designing solutions, and to access enablers of innovation. This connection informs our science and how we think about addressing unmet patient needs. Under a strategic collaboration with FSHD Global Research Foundation, FACIO is committed to evaluating IP created by its research partners and to creating a commercialisation pathway for projects supported by the FOUNDATION.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Facio BioTherapies Pty has never raised funding before.
Facio BioTherapies Pty Tech Stack
Discover the technologies and tools that power Facio BioTherapies Pty's digital infrastructure, from frameworks to analytics platforms.
Databases
Reverse proxies
Programming languages
Blogs
WordPress themes
Page builders
Miscellaneous
Performance
Font scripts
United States
Canada
Portugal
ThailandFrequently asked questions
4.8
40,000 users
